{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:28:13Z","timestamp":1793410093039,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T00:00:00Z","timestamp":1518048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bulcan.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T23:20:09Z","timestamp":1519514409000},"page":"397-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["D\u00e9pistage du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u00a0: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx"],"prefix":"10.1016","volume":"105","author":[{"given":"Marie-Anne","family":"Loriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Barin-Le-Guellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Becquemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bobin-Dubigeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-6522","authenticated-orcid":false,"given":"Alexandre","family":"Harle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-5431","authenticated-orcid":false,"given":"Vianney","family":"Poinsignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hennart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Broly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Fonrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lafay-Chebassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Wozny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadil","family":"Masskouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-311X","authenticated-orcid":false,"given":"Marie-Christine","family":"Etienne-Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.bulcan.2018.02.001_bib0005","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1200\/JCO.2003.10.065","article-title":"Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24\u00a0or 36\u00a0weeks as adjuvant therapy in stages II and III colon cancer: results of a randomized trial","volume":"21","author":"Andre","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.02.001_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.bulcan.2018.02.001_bib0015","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bulcan.2018.02.001_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","article-title":"Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.02.001_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2018.02.001_bib0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","article-title":"Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?","volume":"28","author":"Mercier","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-13-0878","article-title":"microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites","volume":"13","author":"Offer","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.bulcan.2018.02.001_bib0040","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bulcan.2018.02.001_bib0045","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.02.001_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","article-title":"Upfront DPD deficiency detection to secure 5-FU administration: part 2-application to head-and-neck cancer patients","volume":"4","author":"Launay","year":"2017","journal-title":"Clin Cancer Drugs"},{"issue":"9","key":"10.1016\/j.bulcan.2018.02.001_bib0055","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bulcan.2018.02.001_bib0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bulcan.2018.02.001_bib0065","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.bulcan.2018.02.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.bulcan.2018.02.001_bib0075","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.02.001_bib0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","article-title":"Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time","volume":"54","author":"Lunenburg","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2018.02.001_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017\u00a0update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2018.02.001_bib0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cpt.685","article-title":"Quantitative contribution of rs75017182\u00a0to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity","volume":"102","author":"Nie","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000197","article-title":"Association between DPYD c.1129-5923\u00a0C>G\/hapB3\u00a0and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)","volume":"26","author":"Lee","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cpt.531","article-title":"Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population","volume":"101","author":"Elraiyah","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bulcan.2018.02.001_bib0115","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","article-title":"A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy","volume":"28","author":"Ciccolini","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.bulcan.2018.02.001_bib0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cpt.210","article-title":"Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio","volume":"99","author":"Thomas","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bulcan.2018.02.001_bib0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00280-014-2553-2","article-title":"Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy","volume":"74","author":"Carlsson","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.bulcan.2018.02.001_bib0130","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/cncr.26595","article-title":"Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy","volume":"118","author":"Wettergren","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2018.02.001_bib0135","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2018.02.001_bib0140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bcp.12821","article-title":"Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy","volume":"81","author":"van Staveren","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.02.001_bib0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bulcan.2018.02.001_bib0150","first-page":"1","article-title":"Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose capecitabine","author":"Henricks","year":"2017","journal-title":"JCO Precision Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2018.02.001_bib0155","first-page":"2039","article-title":"Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.bulcan.2018.02.001_bib0160","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2018.02.001_bib0165","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","article-title":"Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene","volume":"1862","author":"Kuilenburg","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.bulcan.2018.02.001_bib0170","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u00a0\u2013\u00a0an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bulcan.2018.02.001_bib0175","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.bulcan.2018.02.001_bib0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","article-title":"DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity","volume":"67","author":"Yang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.02.001_bib0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bcp.12790","article-title":"Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer","volume":"81","author":"Launay","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2018.02.001_bib0190","unstructured":"FDA website: http:\/\/www.fda.gov\/drugs\/scienceresearch\/researchareas\/pharmacogenetics\/ucm083378.htm."},{"issue":"8","key":"10.1016\/j.bulcan.2018.02.001_bib0195","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2018.02.001_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.therap.2016.09.007","article-title":"Traitements personnalis\u00e9s gr\u00e2ce \u00e0 la pharmacog\u00e9n\u00e9tique\u00a0: niveaux de preuve et de recommandations du R\u00e9seau national de pharmacog\u00e9n\u00e9tique (RNPGx)","volume":"72","author":"Picard","year":"2017","journal-title":"Therapie"},{"issue":"9","key":"10.1016\/j.bulcan.2018.02.001_bib0205","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/pgs-2016-0006","article-title":"Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines","volume":"17","author":"Cortejoso","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bulcan.2018.02.001_bib0210","article-title":"Prevention of 5-FU-induced health threatening toxicity by pretherapeutic DPD deficiency screening: medical and economic assessment of a multiparametric approach","author":"Boisdron-Celle","year":"2013","journal-title":"ASCO"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118300535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:38:54Z","timestamp":1751416734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118300535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0007455118300535"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9pistage du d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u00a0: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}